Abstract 411P
Background
The cancer, which claims a million deaths per annum across India is a major concern due to presentation in later stages, owing to lack of awareness and structured screening programs. The fragmented screening happens through hospitals (HBS), rural camps by screening buses (CSB), awareness programs, and augmented self-examination (ASE) protocols using AI. This research is aimed to empower cancer screening strategies.
Methods
The effective analysis is based on the number of cancer cases detected and treated effectively. Cost data were collected as a combination of CAPEX and OPEX to do a camp and cost is derived per test using key informant interviews, patient surveys, and other publicly available data sources. A hypothetical cohort of 5,00,000 patients was assumed for assessing each strategy. One-way, two-way, and probabilistic sensitivity analyses were performed to test the robustness of the result. The methods selected were HBS, CSB &ASE.
Results
The results showed augmented self-examination is the best strategy followed by education and lastly screening vehicles. One-way analysis showed that the results were sensitive to the labor cost, but the two-way analysis showed that results are not sensitive to cancer burden. The cost of ASE for 3 cancers (oral, cervical breast) per person is INR 150, for CSB 1200 INR, and for HBS its 650 INR.
Conclusions
ASE is the way forward in developing nations followed by empowering the community health centers and the least effective is cancer screening buses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06